These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 32151708)
21. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689 [TBL] [Abstract][Full Text] [Related]
22. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Hertz DL; Speth KA; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM Breast Cancer Res Treat; 2017 Oct; 165(3):659-668. PubMed ID: 28643023 [TBL] [Abstract][Full Text] [Related]
23. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC Oncology; 2005; 69(6):471-7. PubMed ID: 16410685 [TBL] [Abstract][Full Text] [Related]
24. Use of aromatase inhibitors in breast carcinoma. Santen RJ; Harvey HA Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791 [TBL] [Abstract][Full Text] [Related]
25. Challenges in the endocrine management of breast cancer. Mouridsen HT; Rose C; Brodie AH; Smith IE Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138 [TBL] [Abstract][Full Text] [Related]
26. Emerging role of aromatase inhibitors in the adjuvant setting. Goss PE Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874 [TBL] [Abstract][Full Text] [Related]
27. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Berry J Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441 [TBL] [Abstract][Full Text] [Related]
28. Exemestane in postmenopausal women with early or advanced breast cancer: a review. Bertelli G; Gangadhara S Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090 [TBL] [Abstract][Full Text] [Related]
29. Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. Bertelsen BE; Viste K; Helland T; Hagland M; Søiland H; Geisler J; Lende TH; Lønning PE; Sagen JV; Mellgren G; Almås B J Clin Endocrinol Metab; 2022 Apr; 107(5):1368-1374. PubMed ID: 34958096 [TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040 [TBL] [Abstract][Full Text] [Related]
31. Effects of Dempsey JM; Kidwell KM; Gersch CL; Pesch AM; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM; Hertz DL Pharmacogenomics; 2019 Jun; 20(8):571-580. PubMed ID: 31190621 [No Abstract] [Full Text] [Related]
32. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449 [TBL] [Abstract][Full Text] [Related]
33. New aromatase inhibitors in the treatment of advanced breast cancer. Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510 [TBL] [Abstract][Full Text] [Related]
34. Drug safety evaluation of exemestane. Lintermans A; Neven P; Paridaens R Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848 [TBL] [Abstract][Full Text] [Related]
35. [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects]. Krásenská M Klin Onkol; 2016; 29 Suppl 3():S39-49. PubMed ID: 28118723 [TBL] [Abstract][Full Text] [Related]
36. Role of aromatase inhibitors in the treatment of breast cancer. Choueiri TK; Alemany CA; Abou-Jawde RM; Budd GT Clin Ther; 2004 Aug; 26(8):1199-214. PubMed ID: 15476902 [TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Gibson LJ; Dawson C; Lawrence DH; Bliss JM Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488 [TBL] [Abstract][Full Text] [Related]
38. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. Telford C; Jones N; Livings C; Batson S Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303 [TBL] [Abstract][Full Text] [Related]
39. Anti-aromatase agents in the treatment and prevention of breast cancer. Goss P Cancer Control; 2002; 9(2 Suppl):2-8. PubMed ID: 11965225 [TBL] [Abstract][Full Text] [Related]
40. Aromatase inhibitors in early breast cancer therapy. Smith IE Semin Oncol; 2004 Dec; 31(6 Suppl 12):9-14. PubMed ID: 15719596 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]